Lupin Ltd

About Lupin Ltd

Lupin Ltd. is a global pharmaceutical company primarily engaged in developing, manufacturing, and marketing a wide range of branded and generic formulations, as well as active pharmaceutical ingredients (APIs). With a strong presence in key therapeutic areas like cardiovascular, diabetology, and respiratory, Lupin holds a significant market position in India, the US, and various growth markets worldwide.

Key Financial Ratios of Lupin Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Lupin Ltd's P/E ratio (TTM) is 15.46, compared to the industry median of 30.91 and large cap median of 44.19.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Lupin Ltd's P/B ratio is 4.38, compared to the industry median of 3.69 and large cap median of 6.64.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Lupin Ltd's P/S ratio is 3.51, compared to the industry median of 3.74 and large cap median of 6.84.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Lupin Ltd's PEG ratio is 1.35.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Lupin Ltd's EV/EBITDA ratio is 10.92.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Lupin Ltd's ROE is 23.86%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Lupin Ltd's ROA is 22.98%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Lupin Ltd's ROCE is 30%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Lupin Ltd's operating margin is 31.53%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Lupin Ltd's net margin is 19.15%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Lupin Ltd's current ratio is 1.67.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Lupin Ltd's debt-to-equity ratio is 0.10.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Lupin Ltd's interest coverage ratio is 16.84.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Lupin Ltd's DPS is ₹17.50.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Lupin Ltd's EPS is 62.28.

(Source line: "Ratios as of 24 Sept 2026, based on last traded price of ₹2153. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1968

• Headquarters: Mumbai, Maharashtra

• Core Offerings: Branded Formulations, Generic Formulations, Active Pharmaceutical Ingredients (APIs), Biosimilars, Specialty Products

• Stock Listing: NSE (LUPIN), BSE (500257)

• Promoter: Gupta Family / Desh Bandhu Gupta Family

History of Lupin Ltd

Founded in 1968 by Desh Bandhu Gupta, Lupin initially focused on producing tuberculosis drugs. Over the decades, it expanded its product portfolio and geographical footprint, becoming a global player. Key milestones include its entry into regulated markets like the US, significant investments in R&D for complex generics and specialty products, and strategic acquisitions to bolster its presence. Today, Lupin is one of India's leading pharmaceutical companies with a strong global presence.

Business Segments and Revenue Mix

• India Formulations: Focuses on branded generics, covering a wide range of therapeutic areas such as cardiovascular, central nervous system, diabetes, respiratory, anti-infectives, and women's health. Has a strong sales and marketing network across the country.

• USA: Operates through its subsidiary, Lupin Pharmaceuticals Inc., offering a diverse portfolio of generic and specialty products. It is a key growth driver, with investments in complex generics and biosimilars.

• Growth Markets: Includes operations in Latin America, ASEAN countries, Australia, New Zealand, and Africa, contributing significantly to the company's international revenue and global footprint.

• Active Pharmaceutical Ingredients (API): Manufactures and supplies high-quality APIs for both internal consumption (for its finished dosage forms) and external customers globally, ensuring backward integration and cost efficiencies.

Key Personnel

Nilesh Gupta (Managing Director): Son of founder D.B. Gupta, he has been instrumental in expanding Lupin's global reach and strengthening its R&D capabilities, driving innovation and growth. Vinita Gupta (Chief Executive Officer): Daughter of founder D.B. Gupta, she has spearheaded Lupin's entry and growth in the US market, focusing on strategic partnerships and portfolio diversification.

Subsidiaries and Associate Companies

• Lupin Pharmaceuticals Inc. (USA)

• Lupin Australia Pty Ltd.

• Lupin Europe Ltd. (UK)

• Lupin Mexico SA de CV

• Lupin Brasil Comércio e Participações Ltda.

• Kyowa Pharmaceutical Industry Co. Ltd. (Japan)

Corporate Actions

Lupin has been involved in various product-specific acquisitions and licensing agreements to bolster its portfolio, particularly in specialty and complex generics, and has actively engaged in debt restructuring and fundraising activities as needed. No major recent large-scale bonus/rights issues have been announced recently.

References

1. Annual Report FY2023-24
2. Exchange Filings (NSE/BSE)
3. Financial Results Announcement Q4 FY2024